ArticleMolecular medicine reports2015
MicroRNA‑144 inhibits migration and proliferation in rectal cancer by downregulating ROCK‑1.
Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.Molecular oncology · 2026Article
- Rel-A/PACER/miR 7 Axis May Play a Role in Radiotherapy Treatment in Breast Cancer PatientsIranian biomedical journal · 2023Article
- Tumor-suppressing effects of miR-381-3p in pediatric acute myeloid leukemia via ROCK1 downregulation.Functional & integrative genomics · 2023Article
- CircTUBGCP3 Contributes to the Malignant Progression of Rectal Cancer.Digestive diseases and sciences · 2022Article
- Dysregulation of MiR-144-5p/RNF187 Axis Contributes To the Progression of Colorectal Cancer.Journal of translational internal medicine · 2022Article
- Tetramethylpyrazine Inhibits the Proliferation and Invasion of Glioma Cells by Regulating the UBL7-AS1/miR-144-3p Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Evaluation of Radiotherapy onReports of biochemistry & molecular biology · 2022Article
- hsa‑miR‑15a‑5p inhibits colon cell carcinoma via targeting CCND1.Molecular medicine reports · 2021Article
- Glucocorticoid Receptor β (GRβ): Beyond Its Dominant-Negative Function.International journal of molecular sciences · 2021Review
- Concomitant Up-Regulation ofReports of biochemistry & molecular biology · 2021Article
- Identification of differentially expressed miRNAs after Lactobacillus reuteri treatment in the ileum mucosa of piglets.Genes & genomics · 2020Article
- A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery.Cancers · 2020Article
- Review
- Review
- MicroRNA: Another Pharmacological Avenue for Colorectal Cancer?Frontiers in cell and developmental biology · 2020Review
- MicroRNA-144: A novel biological marker and potential therapeutic target in human solid cancers.Journal of Cancer · 2020Review
- Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.Translational cancer research · 2019Article
- Article
- MicroRNA-144 mediates chronic inflammation and tumorigenesis in colorectal cancer progression via regulating C-X-C motif chemokine ligand 11.Experimental and therapeutic medicine · 2018Article
- miR-202-5p inhibits the migration and invasion of osteosarcoma cells by targeting ROCK1.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of the colon and rectum are two distinct entities, which require different treatment strategies and separate treatment. MicroRNAs (miRNAs) act as critical regulators of genes involved in several biological processes. Aberrant alterations of miRNAs have been found in several types of cancer, including colon cancer and rectal cancer. Extensive catalogues of downregulated miRNAs have been identified for colon cancer, whereas only limited data are available for rectal cancer. An example of miRNA profiling in a previous study found that miRNA (miR)‑144 showed aberrant expression and appeared to be rectal cancer‑specific, its expression not being reported in colon cancer. In the present study, the role of miR‑144 in rectal cancer was investigated. SW837 and SW1463 cell lines were selected as rectal cell carcinoma cells. Using reverse transcription-quantitative polymerase chain reaction, western blot, BrdU, cell migration and cell viability assays, it was found that the expression levels of miR‑144 were significantly reduced in the SW837 and SW1463 cell lines, and the overexpression of miR‑144 suppressed rectal cancer cell viability, migration and proliferation. In addition, Rho‑associated coiled‑coil containing protein kinase 1 (ROCK1) was identified as a target of miR‑144 in the rectal cancer cells. The supplementation of ROCK1 markedly restored the cell migration and proliferation, which was inhibited by miR‑144. Together, the data of the present study demonstrated that miR‑144 acts as a tumor suppressor by targeting ROCK1, and indicates the potential of miR‑144 as a novel biomarker and target in the treatment of rectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.